Fundamental Concepts in the Diagnosis of Advanced NSCLC

Slides:



Advertisements
Similar presentations
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Advertisements

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Genesis Oncology Trust Palliative Care Lecture Series Dr Helen Winter 3 rd July
Non Small Cell lung Cancer Molecular
Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene
Rosell R et al. Proc ASCO 2011;Abstract 7503.
“CASE SERIES OF EGFR MUTATIONS IN SQUAMOUS CELL CARCINOMA LUNG ”
Patient Case 1 Patient Case 1: PET/CT Scan.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Unità Clinica di Diagnostica Istopatologica e Molecolare
NOACs for Cancer-Associated Thrombosis:
Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Advanced NSCLC Without Actionable Mutations
Updates in Hodgkin Lymphoma
New Patient Journeys in Non-small cell lung cancer
Progression After Cancer Immunotherapy in Advanced NSCLC
Ask the Onychomycosis Expert, Part 2
The Genomics of Cancer and Molecular Testing:
New Standards of Care in ALK-Translocated Advanced NSCLC
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Updates in Lung Cancer: Insights From Vienna
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference
Optimizing Management of Advanced Bladder Cancer
EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
More Than Meets the Eye.
Lung Cancer Screening. The Pulmonologist’s Role in Improving Personalized Diagnosis and Treatment of NSCLC.
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Moving Care Forward in Advanced NSCLC
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.
Oral Prostanoids and PAH
Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. Successful tissue collection in patients.
Progress of the NSCLC Revolution
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
Practical Guidance on the Management of Pan-Negative NSCLC
Detection rate for EGFR mutations in cfDNA.
Program Goals Background: Anticoagulation in Patients With VTE.
Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.
Preparing for Checkpoint Inhibitors in Breast Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Debates and Dilemmas, Part 1
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)
Optimizing Characterization of NSCLC Through Specialty Collaboration
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Educational Objectives
Checkpoint Inhibitors in First-Line Advanced NSCLC
Optimizing Outcomes in Patients With NSCLC and Liver Metastases
Third-Generation EGFR TKIs
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Physiologic vs Chronologic Age
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Combining Immunotherapy and Chemotherapy in NSCLC
Physiologic vs Chronologic Age
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Updates in Best Practices in Non-Small Cell Lung Cancer
Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.
Presentation transcript:

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Patient Case 1 62-Year-Old Woman

Patient Case 1 Chest CT

Patient Case 1 PET Scan

Patient Case 1 (cont)

ACCP Guidelines for Diagnosis

EBUS Best Practice Advice From the Experts

EBUS Best Practice Advice From the Experts (cont)

Advanced Nonsquamous NSCLC Negative for Targetable Mutation

Patient Case 1 (cont) Treatment

Quality of Life

Advanced Squamous NSCLC Negative for a Targetable Mutation

Immunotherapy

Patient Case 2 52-Year-Old Female Nonsmoker

Patient Case 2 (cont)

Epidermal Growth Factor Receptor (EGFR) Mutations in NSCLC

Molecular Testing

Patient Case 2 (cont)

Best Practices for Diagnosis

Multidisciplinary Teams

Differentiating Squamous and Nonsquamous NSCLC

Patient Case 2 (cont)

FDA-Approved EGFR TKIs for NSCLC

Resistance to EGFR TKIs

EGFR Therapy vs Chemotherapy Outcomes

ALK Gene Rearrangements

Other Histologies

Summary

Summary (cont)

Abbreviations

Abbreviations (cont)